Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy

Helena Lanzafame, Ilektra A. Mavroeidi, Kim M. Pabst, Mélanie Desaulniers, Marc Ingenwerth, Nader Hirmas, Lukas Kessler, Michael Nader, Timo Bartel, Stephan Leyser, Francesco Barbato, Martin Schuler, Sebastian Bauer, Jens T. Siveke, Ken Herrmann, Rainer Hamacher and Wolfgang P. Fendler
Journal of Nuclear Medicine June 2024, 65 (6) 880-887; DOI: https://doi.org/10.2967/jnumed.123.267248
Helena Lanzafame
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;
2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilektra A. Mavroeidi
2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim M. Pabst
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;
2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mélanie Desaulniers
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;
2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
4Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, Québec, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Ingenwerth
3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany;
5Institute of Pathology, University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nader Hirmas
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;
2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lukas Kessler
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;
2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
6Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Nader
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;
2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timo Bartel
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;
2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephan Leyser
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;
2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Barbato
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;
2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Schuler
2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
7National Center for Tumor Diseases West, Campus Essen, Essen, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Bauer
2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany;
7National Center for Tumor Diseases West, Campus Essen, Essen, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jens T. Siveke
2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
7National Center for Tumor Diseases West, Campus Essen, Essen, Germany; and
8Bridge Institute of Experimental Tumor Therapy and Division of Solid Tumor Translational Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Herrmann
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;
2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
6Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rainer Hamacher
2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang P. Fendler
1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;
2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 65 no. 6 880-887
DOI 
https://doi.org/10.2967/jnumed.123.267248
PubMed 
38724279

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication December 15, 2023
  • Revision received March 15, 2024
  • Published online June 3, 2024.

Article Versions

  • previous version (May 9, 2024 - 10:02).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2024 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Helena Lanzafame1,2,
  2. Ilektra A. Mavroeidi2,3,
  3. Kim M. Pabst1,2,
  4. Mélanie Desaulniers1,2,4,
  5. Marc Ingenwerth3,5,
  6. Nader Hirmas1,2,
  7. Lukas Kessler1,2,6,
  8. Michael Nader1,2,
  9. Timo Bartel1,2,
  10. Stephan Leyser1,2,
  11. Francesco Barbato1,2,
  12. Martin Schuler2,7,
  13. Sebastian Bauer2,3,7,
  14. Jens T. Siveke2,7,8,
  15. Ken Herrmann1,2,6,
  16. Rainer Hamacher*,2,3 and
  17. Wolfgang P. Fendler*,1,2
  1. 1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;
  2. 2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;
  3. 3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany;
  4. 4Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, Québec, Canada;
  5. 5Institute of Pathology, University Hospital Essen, Essen, Germany;
  6. 6Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany;
  7. 7National Center for Tumor Diseases West, Campus Essen, Essen, Germany; and
  8. 8Bridge Institute of Experimental Tumor Therapy and Division of Solid Tumor Translational Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany
  1. For correspondence or reprints, contact Helena Lanzafame (helena.lanzafame{at}uk-essen.de).
View Full Text

Statistics from Altmetric.com

Cited By...

  • 7 Citations
  • 12 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET
    Thomas A. Hope, Jeremie Calais, Ajit H. Goenka, Uwe Haberkorn, Mark Konijnenberg, Jonathan McConathy, Daniela E. Oprea-Lager, Laura Trimnal, Elcin Zan, Ken Herrmann, Christophe M. Deroose
    Journal of Nuclear Medicine 2025 66 1
  • FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?
    Irene García Megías, Ludmila Santiago Almeida, Adriana K. Calapaquí Terán, Kim M. Pabst, Ken Herrmann, Francesco Giammarile, Roberto C. Delgado Bolton
    Annals of Nuclear Medicine 2025 39 5
  • Clinical and research applications of fibroblast activation protein-α inhibitor tracers: a review
    Mélanie Desaulniers, Étienne Rousseau, Kim M Pabst
    British Journal of Radiology 2025
  • 18F-FAPI PET/CT Imaging in a Case of Synovial Sarcoma
    Haopeng Ni, Yanzhao Dong, Sahar Ahmed Abdalbary, Zhenfeng Liu, Hui Lu
    Clinical Nuclear Medicine 2024 49 12
  • 68Ga-FAPI-04 Versus 18F-FDG PET/CT in Duodenal Synovial Sarcoma
    Fenglin Zhan, Xin Liu, Hangcheng Zhou, Xuemei Wang, Xiaobo Yao
    Clinical Nuclear Medicine 2025
  • Evaluating the diagnostic performance of [18F]ALF-NOTA-FAPI-04 PET/CT in gastric cancer: a comparative study with [18F]FDG PET/CT
    Jinghui Lv, Kai Zheng, Chengzhi Jiang, Jian Yang, Xiang Peng, Hui Ye, Yanyin Zhang
    European Radiology 2024 35 6
  • 68Ga-FAPI-04 Outperforms 18F-FDG in Detecting Lesions for Primary Leiomyosarcoma of Bone
    Yaqun Jiang, Yueli Tian, Yong He
    Clinical Nuclear Medicine 2025 50 7
  • Adult Embryonal Rhabdomyosarcoma of the Prostate Presented on 18F-FDG and Al18F-FAPI-74 PET/CT
    Xin Cheng, Guozhu Hou, Rong Zheng, Xi Chen, Xuejuan Wang
    Clinical Nuclear Medicine 2025 50 4
  • Comparison of [68Ga]Ga-Fibroblast Activation Protein Inhibitor–04 and [18F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radiopharmaceutical Therapy
    Rongxi Wang, Jiarou Wang, Jialin Xiang, Huimin Sui, Linlin Li, Chenhao Jia, Xingtong Peng, Xiaoyuan Chen, Zhaohui Zhu, Jingjing Zhang
    Journal of Nuclear Medicine 2025 66 4
  • Differenzierung maligner und benigner peripherer Nervenscheidentumoren mittels (68)Ga-FAPI-PET
    A M Spektor, J Wessendorf, A Helisch, M Schreckenberger, M Röhrich
    Nuklearmedizin - NuclearMedicine 2025 64 01

Article usage

Article usage: May 2024 to April 2025

AbstractFullPdf
May 2024295010568
Jun 202412825245
Jul 20246512929
Aug 20244553825
Sep 2024279219
Oct 20244282415
Nov 20243206317
Dec 20246018994
Jan 20254216979
Feb 20253517957
Mar 20252515259
Apr 202526213129
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 65 (6)
Journal of Nuclear Medicine
Vol. 65, Issue 6
June 1, 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
Helena Lanzafame, Ilektra A. Mavroeidi, Kim M. Pabst, Mélanie Desaulniers, Marc Ingenwerth, Nader Hirmas, Lukas Kessler, Michael Nader, Timo Bartel, Stephan Leyser, Francesco Barbato, Martin Schuler, Sebastian Bauer, Jens T. Siveke, Ken Herrmann, Rainer Hamacher, Wolfgang P. Fendler
Journal of Nuclear Medicine Jun 2024, 65 (6) 880-887; DOI: 10.2967/jnumed.123.267248

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
Helena Lanzafame, Ilektra A. Mavroeidi, Kim M. Pabst, Mélanie Desaulniers, Marc Ingenwerth, Nader Hirmas, Lukas Kessler, Michael Nader, Timo Bartel, Stephan Leyser, Francesco Barbato, Martin Schuler, Sebastian Bauer, Jens T. Siveke, Ken Herrmann, Rainer Hamacher, Wolfgang P. Fendler
Journal of Nuclear Medicine Jun 2024, 65 (6) 880-887; DOI: 10.2967/jnumed.123.267248
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Comparison of [68Ga]Ga-Fibroblast Activation Protein Inhibitor-04 and [18F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radiopharmaceutical Therapy
  • SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Is Long–Axial-Field-of-View PET/CT Cost-Effective? An International Health–Economic Analysis
  • Multicycle Dosimetric Behavior and Dose–Effect Relationships in [177Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy
Show more Clinical Investigation

Similar Articles

Keywords

  • 68Ga-FAPI PET
  • sarcoma
  • fibroblast activation protein
  • theranostic
  • cancer imaging
SNMMI

© 2025 SNMMI

Powered by HighWire